Healsmith M F, Berth-Jones J, Fletcher A, Graham-Brown R A
Department of Dermatology, Leicester Royal Infirmary.
J R Soc Med. 1991 Sep;84(9):524-6. doi: 10.1177/014107689108400907.
We report a series of 11 basal cell carcinomas of various types treated with nine intra-lesional injections of 1.5 million units of interferon alpha-2b. The diagnosis was confirmed histologically in each case. After 3 months' follow-up six tumours had resolved both clinically and histologically. In three cases the tumour size was reduced. One tumour grew larger. Side effects were well tolerated except by one subject who was withdrawn. Those cases which responded have now been followed-up for between 12 and 26 months with no clinical or histological evidence of tumour recurrence. This is the longest period of follow-up so far reported for this novel treatment. The results are encouraging and, if maintained in future series, may indicate a useful role for interferon alpha in the management of this common cutaneous malignancy.
我们报告了一系列11例不同类型的基底细胞癌，用9次瘤内注射150万单位的干扰素α-2b进行治疗。每例均经组织学确诊。经过3个月的随访，6个肿瘤在临床和组织学上均已消退。3例肿瘤大小缩小。1例肿瘤增大。除1例退出研究的受试者外，副作用耐受性良好。那些有反应的病例目前已随访12至26个月，没有肿瘤复发的临床或组织学证据。这是迄今为止报道的这种新疗法最长的随访期。结果令人鼓舞，如果在未来的系列研究中得以维持，可能表明干扰素α在这种常见皮肤恶性肿瘤的治疗中具有有益作用。
